This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SILVER SPRING, Md., March 7, 2013 (GLOBE NEWSWIRE) --
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, emphasized today that the cannabinoid-based treatments for cancer to be developed by its subsidiary, Medical Marijuana Sciences, Inc., may offer a "two-pronged" approach to treating the disease and its associated symptoms.
Cannabis has been used for thousands of years for medical purposes. It has been recognized for its pain-killing properties as well as its ability to alleviate nausea and vomiting and as a result, is presently in
clinical trials for these indications. Over the past few years, cannabinoids found in
Cannabis have been shown to relieve pain associated with cancer as well as the cachexia, or "wasting syndrome," experienced by patients with advanced cancer. Cachexia is characterized by loss of appetite, weight loss, muscle atrophy, weakness, and fatigue.
In contrast to cannabinoids, most cancer drugs and treatments in use today carry with them serious and even life-threatening side effects. A few examples are greatly depressed white blood cell, red blood cell, and platelet counts; these, in turn, can cause greatly increased susceptibility to opportunistic infections, anemia, and internal bleeding. Such side effects often require the use of other drugs to minimize their occurrence and damage. These deleterious side effects can limit the amounts of drugs that can be given to patients and, therefore, the degree to which the cancer drugs can "kill" the tumors where they were directed.
Therefore, there appears to be a marked difference in the deleterious side effects associated with commonly-used anticancer drugs and the "beneficial" side effects associated with cannabinoids. Medical Marijuana Sciences, Inc. plans to develop treatments for two of the most deadly forms of cancer, namely cancers of the brain and pancreas, that are based on cannabinoids. By doing so, the Company should be able to treat both the cancer itself, and potentially, the other deleterious symptoms (pain and cachexia, for example) associated with it.